NCT01879540View on ClinicalTrials.gov

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Human Influenza
Interventions
BIOLOGICAL

aTIV

Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)

Trial Locations (1)

2610

Antwerp University Centre for the Evaluation of Vaccination, Antwerp

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01879540 - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age | Biotech Hunter | Biotech Hunter